IL22 and neoplasm: Furthermore, in vitro analysis on TNBC cell lines (MDA-MB-231 and MDA-MB-468) also showed that through the activation of STAT3/MAPKs/AKT pathway, IL-22 enhances tumor cell migration and their resistance to paclitaxel chemotherapy in a dose-dependent manner [94].